US 11,666,650 B2
Immune composition comprising respiratory syncytial virus (RSV) G polypeptide
Gan Zhao, Suzhou (CN); Aihua Dong, Suzhou (CN); Zhonghuai He, Suzhou (CN); Qingling Yu, Suzhou (CN); and Cheng Sui, Suzhou (CN)
Assigned to ADVACCINE (SUZHOU) BIOPHARMACEUTICALS CO. LTD., Suzhou (CN)
Filed by ADVACCINE (SUZHOU) BIOPHARMACEUTICALS CO. LTD., Suzhou (CN)
Filed on Aug. 5, 2020, as Appl. No. 16/985,736.
Claims priority of provisional application 62/885,370, filed on Aug. 12, 2019.
Prior Publication US 2021/0113683 A1, Apr. 22, 2021
Int. Cl. C12N 7/00 (2006.01); A61K 39/155 (2006.01); A61P 31/14 (2006.01); A61K 9/08 (2006.01); A61K 38/13 (2006.01)
CPC A61K 39/155 (2013.01) [A61K 9/08 (2013.01); A61K 38/13 (2013.01); A61P 31/14 (2018.01); C12N 2760/18522 (2013.01); C12N 2760/18534 (2013.01); C12N 2760/18571 (2013.01)] 12 Claims
OG exemplary drawing
 
1. An immune composition, comprising (i) a modified respiratory syncytial virus (RSV) G polypeptide or a nucleic acid encoding the modified RSV G polypeptide, and (ii) an immune regulator;
wherein the modified RSV polypeptide lacks a transmembrane domain as compared with the wild-type counterpart,
wherein the modified RSV G polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:1-4;
wherein the immune regulator is cyclosporin A; and
wherein the immune composition further comprises a non-ionic surfactant, which comprises polyethylene glycol (15)-hydroxystearate.